HR 5160 Re-checks Congress.gov for new actions and updates the bill's status, and fills in any sponsors, committees, or related bills that are missing. It does not re-pull sponsors/cosponsors/committees/related — those rarely change — and it skips all work if nothing has changed upstream, so it's cheap to click.
Stem Cell Therapeutic and Research Reauthorization Act of 2025
Summary
- Reauthorizes federal funding for the C.W. Bill Young Cell Transplantation Program with $33 million annually for fiscal years 2027 through 2031.
- Changes the cord blood inventory requirement from a specific target of 150,000 units to "a sufficient supply" as determined by the Secretary of Health and Human Services.
- Allows the Secretary to transfer cord blood from non-operational banks to other qualified banks to ensure continued availability.
- Requires the Secretary to manage the National Cord Blood Inventory based on current scientific and clinical information to maximize clinical utility and ensure genetic diversity.
- Defines "high quality cord blood unit" as meeting current industry standards and Food and Drug Administration requirements.
AI-generated plain-language summary of the bill text — neutral, and may be imperfect. See the full text below for the exact wording.
Sponsor (1)
21 cosponsors
- Del. Norton, Eleanor Holmes [D-DC-At Large] (D-DC)
- Rep. Aderholt, Robert B. [R-AL-4] (R-AL)
- Rep. Barragán, Nanette Diaz [D-CA-44] (D-CA)
- Rep. Bentz, Cliff [R-OR-2] (R-OR)
- Rep. Bilirakis, Gus M. [R-FL-12] (R-FL)
- Rep. Castor, Kathy [D-FL-14] (D-FL)
- Rep. Davids, Sharice [D-KS-3] (D-KS)
- Rep. Dingell, Debbie [D-MI-6] (D-MI)
- Rep. Finstad, Brad [R-MN-1] (R-MN)
- Rep. Fischbach, Michelle [R-MN-7] (R-MN)
- Rep. Fitzpatrick, Brian K. [R-PA-1] (R-PA)
- Rep. Garbarino, Andrew R. [R-NY-2] (R-NY)
- Rep. Gottheimer, Josh [D-NJ-5] (D-NJ)
- Rep. Lawler, Michael [R-NY-17] (R-NY)
- Rep. Malliotakis, Nicole [R-NY-11] (R-NY)
- Rep. Matsui, Doris O. [D-CA-7] (D-CA)
- Rep. Mfume, Kweisi [D-MD-7] (D-MD)
- Rep. Morrison, Kelly [D-MN-3] (D-MN)
- Rep. Pingree, Chellie [D-ME-1] (D-ME)
- Rep. Tenney, Claudia [R-NY-24] (R-NY)
- Rep. Vindman, Eugene Simon [D-VA-7] (D-VA)
Money behind the sponsor
Top reported contributors to Christopher H. Smith’s campaign committee (2024 cycle) — who funds the bill’s sponsor, not a claim about this bill. Data from FEC.
- WINDMILL HEALTH PRODUCTS $6,600
- ZAIS GROUP, LLC $6,600
- BLUFF POINT ASSOCIATES $6,600
- HILL & COMPANY $6,600
- SAKER SHOP RITE $6,600
Organizations whose employees gave the most — itemized individual contributions grouped by the donor’s reported employer (FEC Schedule A). Full finance for Christopher H. Smith → · Outside spending →
Actions (16)
- Jul 21, 2026 Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 464. · senate
- Jul 20, 2026 Motion to reconsider laid on the table Agreed to without objection. · house
- Jul 20, 2026 On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H4642) · house
- Jul 20, 2026 Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H4642)
- Jul 20, 2026 DEBATE - The House proceeded with forty minutes of debate on H.R. 5160. · house
- Jul 20, 2026 Considered under suspension of the rules. (consideration: CR H4642-4643) · house
- Jul 20, 2026 Mr. Guthrie moved to suspend the rules and pass the bill, as amended. · house
- Jul 2, 2026 Placed on the Union Calendar, Calendar No. 629. · house
- Jul 2, 2026 Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-724. · house
- May 21, 2026 Ordered to be Reported (Amended) by the Yeas and Nays: 48 - 0. · house
- May 21, 2026 Committee Consideration and Mark-up Session Held · house
- May 13, 2026 Forwarded by Subcommittee to Full Committee by Voice Vote. · house
- May 13, 2026 Subcommittee Consideration and Mark-up Session Held · house
- Sep 4, 2025 Referred to the Subcommittee on Health. · house
- Sep 4, 2025 Referred to the House Committee on Energy and Commerce. · house
- Sep 4, 2025 Introduced in House
More bills on these subjects (8)
Other bills that carry the most legislative subjects in common with this one (topical discovery — distinct from the procedural related bills above).
Similar bills (6)
Bills with similar text or summary — includes reintroductions across Congresses. Ranked by semantic similarity of the bill text (computed locally); a neutral discovery aid, not a claim the bills are duplicates.
Text versions (4)
Bills are re-published as they move (Introduced → Reported → Engrossed → Enrolled …). Each stage below is a separate text; pick two to see what changed. Data from Congress.gov.
Committee action
What happened to this bill in committee — the meetings where it was considered and every recorded vote taken on it.
Meetings where this bill was on the agenda
Full text
AN ACT
To reauthorize the Stem Cell Therapeutic and Research Act of 2005, and for other purposes.
Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the “Stem Cell Therapeutic and Research Reauthorization Act of 2025”.
SEC. 2. REAUTHORIZATION OF THE C.W. BILL YOUNG CELL TRANSPLANTATION PROGRAM.
Section 379B of the Public Health Service Act (42 U.S.C. 274m) is amended—
(1) by striking “appropriated $31,009,000” and inserting the following: “appropriated—
“(1) $31,009,000”;
(2) in paragraph (1), as so inserted, by striking the period at the end and inserting “; and”; and
(3) by adding at the end the following:
“(2) $33,009,000 for each of fiscal years 2027 through 2031.”.
SEC. 3. CORD BLOOD INVENTORY.
(a) In General.—Section 2(a) of the Stem Cell Therapeutic and Research Act of 2005 (42 U.S.C. 274k note) is amended by striking “at least 150,000 new units of high-quality cord blood” and inserting “a sufficient supply, as determined by the Secretary, of high-quality cord blood units”.
(b) Application.—Section 2(c) of such Act (42 U.S.C. 274k note) is amended—
(1) in paragraph (2), by striking “in perpetuity or”; and
(2) by amending paragraph (5) to read as follows:
“(5) if the Secretary determines through an assessment, or through petition by the applicant, that a cord blood bank is no longer operational, does not meet the requirements described in subsection (d)(4), or does not meet the requirements of section 379(d)(4) of the Public Health Service Act, and as a result may not distribute the high-quality units, the Secretary may transfer the units collected pursuant to this section to another qualified cord blood bank or entity approved by the Secretary to ensure continued availability of high-quality cord blood units.”.
(c) Duration of Contracts.—Section 2(d)(4) of such Act (42 U.S.C. 274k note) is amended to read as follows:
“(4) Consideration of best science.—The Secretary shall take into consideration current scientific and clinical information in order to maximize the availability of high- quality cord blood units meeting applicable clinical and quality standards for transplant when entering into contracts under this section, or when extending a period of funding under such a contract under paragraph (2).”.
(d) Inventory Management.—Section 2 of such Act (42 U.S.C. 274k note) is amended—
(1) by redesignating subsections (e), (f), and (g) and as subsections (f), (g), and (h), respectively; and
(2) by inserting after subsection (d) the following:
“(e) Inventory Management.—
“(1) In general.—The Secretary shall manage the size and composition of the National Cord Blood Inventory to maximize clinical utility, ensure genetic diversity, and promote the efficient use of resources.
“(2) Considerations.—In carrying out paragraph (1), the Secretary may—
“(A) on the Secretary’s own initiative or upon petition by a qualified cord blood bank, make determinations regarding the continued storage of cord blood units based on the best available scientific and clinical evidence; or
“(B) prioritize the collection, retention, or disposition of cord blood units based on scientific, clinical, or operational considerations that the Secretary determines to be relevant.”.
(e) Definitions.—Section 2(g) of such Act, as redesignated by subsection (d)(1) of this section, is amended—
(1) by redesignating paragraphs (4) and (5) as paragraphs
(5) and (6), respectively; and
(2) by inserting after paragraph (3) the following:
“(4) The term ‘high quality cord blood unit’ means a cord blood unit that meets current industry standards and any requirements of the Food and Drug Administration.”.
(f) Authorization of Appropriations.—Section 2(h) of such Act, as redesignated by subsection (d)(1) of this section, is amended by striking “fiscal years 2022 through 2026” and inserting “fiscal years 2027 through 2031”.
Passed the House of Representatives July 20, 2026.
Attest:
Clerk. 119th CONGRESS
2d Session
H. R. 5160
AN ACT
To reauthorize the Stem Cell Therapeutic and Research Act of 2005, and for other purposes.
Comments